Access all of the content
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and the use of ctDNA as a biomarker for combined analyses predicting outcomes for adjuvant melanoma.
The abstract entitled ‘Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIBD/IV melanoma treated with adjuvant immunotherapy (CheckMate 915)‘ Abstract LBA31, was presented at European Society for Medical Oncology (ESMO) 2022.
Watch Dr Georgina Long’s top highlights in melanoma at ESMO 2022
- What is known about the clinical utility of circulating tumour DNA in patients with resectable melanoma, and what did the CheckMate 915 study show? (0:11)
- What were the aims and designs of the analysis of the CheckMate 915 study? (2:08)
- What can we conclude about the usefulness of ctDNA as a biomarker, and what further research is needed? (3:01)
Disclosures: Georgina Long has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Dermatological Cancers
Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
The STARBOARD trial will investigate encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the mechanisms of encorafenib, binimetinib and pembrolizumab, as well as details on the STARBOARD trial. The presentation entitled […]
Ryan Sullivan, AACR 2023: Current therapeutic options for BRAF V600 mutated melanoma
Multiple therapies that have been approved for the treatment of BRAF V600 mutated melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the current treatment paradigm and its limitations. Ryan Sullivan presented an abstract entitled ‘Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + […]
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]